Zogenix drug cuts seizure rate in severe epilepsy, sending stock skyrocketing
The company's drug significantly reduced seizure activity compared to a placebo in children with Dravet syndrome, a rare and severe type of epilepsy.
Zogenix (ZGNX) closed out September’s crammed clinical trial calendar with an impressive win.
The small biotech company, based in Emeryville, Calif., said its lead drug, ZX008, significantly reduced seizure activity compared to
